Journal of Diabetology

REVIEW ARTICLE
Year
: 2019  |  Volume : 10  |  Issue : 2  |  Page : 57--61

Implications of CVD-REAL 2 study for Indian diabetic population


Rajeev Chawla1, Shalini Jaggi2 
1 North Delhi Diabetes Centre, New Delhi, India
2 Dr. Mohan's Diabetes Specialities Centre, New Delhi, India

Correspondence Address:
Dr. Rajeev Chawla
North Delhi Diabetes Centre, 180, Jai Apartment, Rohini, Sector 9, New Delhi - 110 085
India

South Asians are reported to have a higher risk of developing macrovascular complications of Diabetes, i.e., coronary artery and cerebrovascular diseases as compared to Caucasians. Literature evidence has shown that among the currently available agents, the sodium/glucose cotransporter 2 inhibitors (SGLT2i) offer a rational approach for management of T2DM over other glucose lowering therapies because of their insulinindependent action, modest weight loss, mild reduction in BP and low risk of hypoglycaemia. Recently, CVDREAL 2 study was conducted across six countries (Israel, Canada, South Korea, Japan, Singapore and Australia) to determine the CV benefits of various SGLT2i in >400,000 T2DM patients in a realworld scenario. Around 75% of the patients in this study were from the AsiaPacific region. Among all the available SGLT2i, most of the study population was exposed to dapagliflozin, contributing to 75% of the total exposure time. The CVDREAL 2 study favoured SGLT2i over other glucose lowering drugs for lower risk of death, HHF, MI and stroke. All these points suggest that the results of CVDREAL 2 study can be incorporated in the high CVD risk Indian population who need much more aggressive treatment for diabetes than other patient populations.


How to cite this article:
Chawla R, Jaggi S. Implications of CVD-REAL 2 study for Indian diabetic population.J Diabetol 2019;10:57-61


How to cite this URL:
Chawla R, Jaggi S. Implications of CVD-REAL 2 study for Indian diabetic population. J Diabetol [serial online] 2019 [cited 2019 Oct 13 ];10:57-61
Available from: http://www.journalofdiabetology.org/article.asp?issn=2078-7685;year=2019;volume=10;issue=2;spage=57;epage=61;aulast=Chawla;type=0